Aktis Oncology, Inc. Common stock Market Cap ($756.70 Million)
Market Cap & Net Worth: Aktis Oncology, Inc. Common stock (AKTS)
Aktis Oncology, Inc. Common stock market cap. Aktis Oncology, Inc. Common stock (NASDAQ:AKTS) has a market capitalization of $756.70 Million ($756.70 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9806 globally and #2704 in its home market, demonstrating a -5.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aktis Oncology, Inc. Common stock's stock price $14.94 by its total outstanding shares 50649450 (50.65 Million). Also see how efficiently does Aktis Oncology, Inc. Common stock generate cash for how efficiently the company converts equity into cash flow.
Aktis Oncology, Inc. Common stock Market Cap History (2015–2026)
Aktis Oncology, Inc. Common stock market cap history from 2015 to 2026. Data shows growth from $81.04 Million to $756.70 Million (13.33% CAGR). Check AKTS stock price and chart for real-time trading data and today's change.
Aktis Oncology, Inc. Common stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aktis Oncology, Inc. Common stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore AKTS net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.07x
Aktis Oncology, Inc. Common stock's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $619.44 Million | $1.79 Million | -$40.87 Million | 346.06x | N/A |
| 2020 | $619.44 Million | $1.79 Million | -$40.87 Million | 346.06x | N/A |
| 2021 | $338.34 Million | $15.35 Million | -$59.19 Million | 22.04x | N/A |
| 2021 | $338.34 Million | $6.62 Million | -$46.92 Million | 51.12x | N/A |
| 2022 | $142.83 Million | $15.35 Million | -$59.19 Million | 9.30x | N/A |
| 2023 | $42.24 Million | $27.12 Million | -$28.64 Million | 1.56x | N/A |
| 2023 | $42.24 Million | $27.12 Million | -$63.56 Million | 1.56x | N/A |
| 2024 | $1.88 Million | $1.49 Million | -$43.98 Million | 1.27x | N/A |
| 2024 | $1.88 Million | $27.38 Million | -$167.95 Million | 0.07x | N/A |
Competitor Companies of AKTS by Market Capitalization
Companies near Aktis Oncology, Inc. Common stock in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Aktis Oncology, Inc. Common stock for a full breakdown of the balance sheet.
Key companies related to Aktis Oncology, Inc. Common stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Aktis Oncology, Inc. Common stock (2015–2026)
Market capitalization of Aktis Oncology, Inc. Common stock from 2015 to today. Between 2015 and today, Aktis Oncology, Inc. Common stock's market cap moved from $81.04 Million to $ 756.70 Million, with a yearly change of 13.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $756.70 Million | +40061.29% |
| 2024 | $1.88 Million | -95.54% |
| 2023 | $42.24 Million | -70.43% |
| 2022 | $142.83 Million | -57.78% |
| 2021 | $338.34 Million | -45.38% |
| 2020 | $619.44 Million | +52.88% |
| 2019 | $405.20 Million | +60.97% |
| 2018 | $251.73 Million | -20.22% |
| 2017 | $315.55 Million | +5.95% |
| 2016 | $297.82 Million | +267.50% |
| 2015 | $81.04 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Aktis Oncology, Inc. Common stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $756.70 Million USD |
| MoneyControl | $756.70 Million USD |
| MarketWatch | $756.70 Million USD |
| marketcap.company | $756.70 Million USD |
| Reuters | $756.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more